NO20042676L - 3-beta-d-ribofuranolsyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav - Google Patents

3-beta-d-ribofuranolsyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav

Info

Publication number
NO20042676L
NO20042676L NO20042676A NO20042676A NO20042676L NO 20042676 L NO20042676 L NO 20042676L NO 20042676 A NO20042676 A NO 20042676A NO 20042676 A NO20042676 A NO 20042676A NO 20042676 L NO20042676 L NO 20042676L
Authority
NO
Norway
Prior art keywords
ribofuranolsylthiazolo
beta
pyrimidine nucleosides
nucleosides
pyrimidine
Prior art date
Application number
NO20042676A
Other languages
English (en)
Norwegian (no)
Inventor
Stephen E Webber
Devron R Averett
Jospeh R Lennox
Erik J Rueden
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of NO20042676L publication Critical patent/NO20042676L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Joints Allowing Movement (AREA)
NO20042676A 2001-11-27 2004-06-25 3-beta-d-ribofuranolsyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav NO20042676L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33346001P 2001-11-27 2001-11-27
PCT/US2002/038001 WO2003045968A1 (fr) 2001-11-27 2002-11-27 Nucleosides 3-$g(b)-d-ribofuranosylthiazolo[4,5-d]pyridimine, et leurs utilisations

Publications (1)

Publication Number Publication Date
NO20042676L true NO20042676L (no) 2004-08-24

Family

ID=23302891

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042676A NO20042676L (no) 2001-11-27 2004-06-25 3-beta-d-ribofuranolsyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav

Country Status (28)

Country Link
US (3) US6924271B2 (fr)
EP (1) EP1451203B1 (fr)
JP (1) JP4493337B2 (fr)
KR (1) KR100718371B1 (fr)
CN (2) CN101033242A (fr)
AP (1) AP2004003069A0 (fr)
AT (1) ATE448238T1 (fr)
AU (1) AU2002365412B2 (fr)
BR (1) BR0214407A (fr)
CA (1) CA2468552C (fr)
CO (1) CO5590931A2 (fr)
DE (1) DE60234376D1 (fr)
EA (1) EA008380B1 (fr)
EC (1) ECSP045167A (fr)
ES (1) ES2333945T3 (fr)
GE (1) GEP20074099B (fr)
HR (1) HRP20040541A2 (fr)
IL (1) IL162137A0 (fr)
IS (1) IS7283A (fr)
MA (1) MA27156A1 (fr)
MX (1) MXPA04004966A (fr)
NO (1) NO20042676L (fr)
NZ (1) NZ533628A (fr)
OA (1) OA12729A (fr)
TN (1) TNSN04113A1 (fr)
UA (1) UA79764C2 (fr)
WO (1) WO2003045968A1 (fr)
YU (1) YU45204A (fr)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142202A1 (en) * 2000-12-08 2006-06-29 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US7030129B2 (en) * 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
EP1599726A4 (fr) * 2003-02-27 2009-07-22 3M Innovative Properties Co Modulation selective d'une activite biologique induite par le recepteur tlr
WO2004078138A2 (fr) 2003-03-04 2004-09-16 3M Innovative Properties Company Traitement prophylactique de la neoplasie epidermique induite par les uv
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
KR20050109562A (ko) * 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
AU2004229478B2 (en) 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
CA2533128A1 (fr) * 2003-07-31 2005-02-10 3M Innovative Properties Company Compositions bioactives comprenant des triazines
WO2005018556A2 (fr) 2003-08-12 2005-03-03 3M Innovative Properties Company Composes contenant une structure imidazo a substitution hydroxylamine
US20050048072A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
RU2006105101A (ru) 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
EP1667694B1 (fr) 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Ligands tlr7 destines au traitement du virus de l'hepatite c
WO2005023190A2 (fr) 2003-09-05 2005-03-17 3M Innovative Properties Company Traitement pour le lymphome a cellules b cd5+
EP1664342A4 (fr) * 2003-09-17 2007-12-26 3M Innovative Properties Co Modulation selective de l'expression de genes tlr
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
AU2004285575A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
CA2545774A1 (fr) 2003-11-14 2005-06-02 3M Innovative Properties Company Composes d'un anneau d'imidazo substitues par oxime
US8598192B2 (en) 2003-11-14 2013-12-03 3M Innovative Properties Company Hydroxylamine substituted imidazoquinolines
AR046781A1 (es) 2003-11-25 2005-12-21 3M Innovative Properties Co Derivados de imidazoquinolinas. composiciones farmaceuticas.
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
JP2007513165A (ja) * 2003-12-02 2007-05-24 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物を含む併用薬および治療方法
WO2005066170A1 (fr) 2003-12-29 2005-07-21 3M Innovative Properties Company Imidazoquinolines a substitution arylalcenyle et arylalkynyle
CA2551399A1 (fr) 2003-12-30 2005-07-21 3M Innovative Properties Company Sulfonamides d'imidazoquinolinyle, d'imidazopyridinyle et d'imidazonaphtyridinyle
WO2005067500A2 (fr) * 2003-12-30 2005-07-28 3M Innovative Properties Company Amelioration de la reponse immunitaire
AU2005228150A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
CA2562283A1 (fr) * 2004-04-09 2005-11-24 3M Innovative Properties Company Methodes, compositions et preparations pour administration de modificateurs de reponse immunitaire (irm)
CA2564855A1 (fr) * 2004-04-28 2005-10-28 3M Innovative Properties Company Compositions et methodes pour vaccination muqueuse
HUE026644T2 (en) 2004-05-28 2016-07-28 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
AU2004320625B2 (en) 2004-06-07 2009-08-27 Anadys Pharmaceuticals, Inc. 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
WO2005123080A2 (fr) 2004-06-15 2005-12-29 3M Innovative Properties Company Imidazoquinolines et imidazonaphthyridines substituees par un heterocyclyle contenant un azote
WO2006065280A2 (fr) 2004-06-18 2006-06-22 3M Innovative Properties Company Composes a noyau imidazo a substitutif d'isoxazole, de dihydroisoxazole et d'oxadiazole
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (fr) 2004-06-18 2006-04-13 3M Innovative Properties Company Imidazonaphthyridines substituees par aryle
WO2006026470A2 (fr) * 2004-08-27 2006-03-09 3M Innovative Properties Company Compositions immunostimulatrices contre le vih
JP2008515928A (ja) * 2004-10-08 2008-05-15 スリーエム イノベイティブ プロパティズ カンパニー Ｄｎａワクチンのためのアジュバント
ES2459368T3 (es) * 2004-12-17 2014-05-09 Anadys Pharmaceuticals, Inc. Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
JP2008526765A (ja) 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 皮膚転移の処置
EP1831226B1 (fr) 2004-12-30 2012-08-08 3M Innovative Properties Company Composes chiraux tetracycliques incitant la biosynthese d'interferon
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
CA2597587A1 (fr) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Composes cycliques imidazo[4,5-c] substitues par oxime et hydroxylamine et procedes associes
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
WO2006107853A2 (fr) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines et analogues associes
JP5242375B2 (ja) 2005-04-01 2013-07-24 ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア ホスホノ−ペント−２−エン−１−イルヌクレオシド及び類似体
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP2614709A1 (fr) 2005-07-18 2013-07-17 Novartis AG Petit modèle d'animal pour une réplication du VHC
WO2007041632A2 (fr) * 2005-09-30 2007-04-12 Scynexis, Inc. Procedes et compositions pharmaceutiques pour traiter et prevenir une infection par le virus de l'hepatite c
WO2007041631A1 (fr) 2005-09-30 2007-04-12 Scynexis, Inc. Derives d'arylalkyle et d'heteroarylalkyle de cyclosporine a utilises pour traiter et prevenir une infection virale
WO2007052055A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins avec adjuvant comprenant des antigenes sans virions prepares a partir de virus influenza eleves en culture cellulaire
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
CA2628424A1 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Vaccins influenza avec adjuvant comprenant des agents d'induction de cytokines
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
CA2630463C (fr) 2005-11-21 2015-01-06 Anadys Pharmaceuticals, Inc. Nouveau procede pour la preparation de 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
EP1988896A4 (fr) 2006-02-22 2011-07-27 3M Innovative Properties Co Conjugués du modificateur de réponse immune
EP2010530A2 (fr) * 2006-03-23 2009-01-07 Novartis AG Procedes de preparation de composes contenant de l'imidazole
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (fr) * 2006-03-23 2007-09-27 Novartis Ag Composes de potentialisation immunitaire
WO2007110776A1 (fr) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Stockage de vaccins antigrippaux sans refrigeration
EP2019686B1 (fr) 2006-03-31 2012-07-11 Novartis AG Immunisation mucosale et parentérale combinée contre le vih
EP2518079A3 (fr) 2006-04-11 2012-12-12 Novartis AG Inhibiteurs du VHC/VIH et leur utilisation
CL2007001427A1 (es) * 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CA2655904C (fr) * 2006-06-22 2014-11-18 Anadys Pharmaceuticals, Inc. Promedicaments de 5-amino-3-(3'-deoxy-beta-d-ribofuranosyl)- thiazolo¬4,5-d|pyrimidin-2,7-dione
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
EP2040712B1 (fr) * 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Promédicaments à groupes fonctionnels carbonate et carbamate de thiazolo [4,5-d] pyrimidines
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (fr) 2006-08-16 2013-08-14 Novartis AG Immunogènes d'Escherischia coli pathogènes des voies urinaires
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
WO2008069917A2 (fr) 2006-11-20 2008-06-12 Scynexis, Inc. Nouveaux peptides cycliques
JP2011506264A (ja) 2006-12-06 2011-03-03 ノバルティス アーゲー インフルエンザウイルスの４つの株に由来する抗原を含むワクチン
KR100880298B1 (ko) * 2006-12-06 2009-01-28 애나디스 파마슈티칼스, 인코포레이티드 ３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리미딘뉴클레오시드 및 이의 용도
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2008127613A1 (fr) * 2007-04-11 2008-10-23 Scynexis, Inc. Compositions pharmaceutiques inédites
PT2185191E (pt) 2007-06-27 2012-11-27 Novartis Ag Vacinas contra a gripe com baixo teor de aditivos
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009026292A1 (fr) * 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Procédés de dosage pour le traitement de pathologies
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US8536114B2 (en) * 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
WO2010100632A2 (fr) 2009-03-06 2010-09-10 Novartis Ag Antigènes de chlamydia
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
EP2419129A2 (fr) 2009-04-14 2012-02-22 Novartis AG Compositions pour l'immunisation contre staphylococcus aureus
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
EP4183412B1 (fr) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Compositions à base de protéine f du vrs et procédés de fabrication associés
CA2768343A1 (fr) 2009-07-16 2011-01-20 Novartis Ag Immunogenes d'escherichia coli detoxifies
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
EP2519265B1 (fr) 2009-12-30 2018-11-14 GlaxoSmithKline Biologicals SA Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
CN102933267B (zh) 2010-05-28 2015-05-27 泰特里斯在线公司 交互式混合异步计算机游戏基础结构
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN103179966B (zh) 2010-10-08 2017-03-15 诺瓦提斯公司 磺酰胺ns3抑制剂的维生素e制剂
ES3018416T3 (es) 2011-01-26 2025-05-16 Glaxosmithkline Biologicals Sa Régimen de inmunización del VRS
CN102153548B (zh) * 2011-02-24 2012-11-28 河北大学 一种含有噻唑（嗪）烷酮环的类核苷衍生物及其制备方法和其在药物制剂中的应用
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
BR112013031028A2 (pt) 2011-06-03 2016-11-29 3M Innovative Properties Co conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
EP3153180A1 (fr) 2011-06-03 2017-04-12 3M Innovative Properties Company Lieurs hétérobifonctionnels avec segments de polyéthylène glycol et conjugués de modificateur de réponse immunitaire fabriqués à partir de ceux-ci
CN103764171B (zh) 2011-07-08 2016-08-17 诺华股份有限公司 酪氨酸连接方法
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
WO2013108272A2 (fr) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Vaccin antipaludique ciblant le stade sanguin
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
MX2015004171A (es) 2012-10-02 2015-10-22 Glaxosmithkline Biolog Sa Conjugados de sacaridos no lineales.
CN105142666A (zh) 2012-11-30 2015-12-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
PT2941233T (pt) 2013-01-07 2020-11-13 Univ Pennsylvania Composições e métodos para tratar linfoma cutâneo de células t
EP2870974A1 (fr) 2013-11-08 2015-05-13 Novartis AG Vaccins conjugués de salmonelle
EP3092256B1 (fr) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Composés et compositions pour l'immunothérapie
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
DK4001311T3 (da) 2014-07-09 2026-02-02 Birdie Biopharmaceuticals Inc Anti-pd-l1/pd-1-kombinationer til behandling af tumorer
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
EP3349717A4 (fr) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. Approches pour améliorer l'hydratation ou l'humidification de la peau
WO2017059280A1 (fr) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Nouveaux inhibiteurs de pan-tam et doubles inhibiteurs de mer/axl
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
FI3641771T3 (fi) 2017-06-23 2026-08-11 Birdie Biopharmaceuticals Inc Farmaseuttisia koostumuksia
MX387358B (es) 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
AU2019274654B2 (en) 2018-05-23 2023-07-20 Pfizer Inc. Antibodies specific for CD3 and uses thereof
US11525010B2 (en) 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
WO2020128893A1 (fr) 2018-12-21 2020-06-25 Pfizer Inc. Traitements combinés de cancer comprenant un agoniste de tlr
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
WO2023196458A1 (fr) * 2022-04-06 2023-10-12 VenatoRx Pharmaceuticals, Inc. Analogues nucléosidiques biodisponibles par voie orale
AU2024381207A1 (en) 2023-11-17 2026-05-14 Institut National de la Santé et de la Recherche Médicale Antineoplastic combinations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746651A (en) 1983-11-01 1988-05-24 Scripps Clinic And Research Foundation Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives
GB8712745D0 (en) 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds
US5041426A (en) * 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
GB9015914D0 (en) 1990-07-19 1990-09-05 Wellcome Found Heterocyclic compounds
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
GB9105899D0 (en) 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US6509320B1 (en) * 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
AU727177B2 (en) * 1996-10-16 2000-12-07 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B

Also Published As

Publication number Publication date
AU2002365412B2 (en) 2008-10-09
AP2004003069A0 (en) 2004-06-30
MA27156A1 (fr) 2005-01-03
EP1451203B1 (fr) 2009-11-11
CN1612889A (zh) 2005-05-04
AU2002365412A1 (en) 2003-06-10
CA2468552A1 (fr) 2003-06-05
JP4493337B2 (ja) 2010-06-30
EA008380B1 (ru) 2007-04-27
ATE448238T1 (de) 2009-11-15
TNSN04113A1 (en) 2006-06-01
GEP20074099B (en) 2007-05-10
KR20040065230A (ko) 2004-07-21
WO2003045968A1 (fr) 2003-06-05
ES2333945T3 (es) 2010-03-03
CN101033242A (zh) 2007-09-12
DE60234376D1 (de) 2009-12-24
CN1300165C (zh) 2007-02-14
CA2468552C (fr) 2011-09-20
US20030199461A1 (en) 2003-10-23
EP1451203A1 (fr) 2004-09-01
NZ533628A (en) 2006-07-28
BR0214407A (pt) 2004-10-19
CO5590931A2 (es) 2005-12-30
US20050182001A1 (en) 2005-08-18
HRP20040541A2 (en) 2004-10-31
US6924271B2 (en) 2005-08-02
UA79764C2 (en) 2007-07-25
US20080090844A1 (en) 2008-04-17
IL162137A0 (en) 2005-11-20
EA200400735A1 (ru) 2004-12-30
ECSP045167A (es) 2004-10-26
JP2005515196A (ja) 2005-05-26
YU45204A (sh) 2006-08-17
OA12729A (en) 2006-06-28
MXPA04004966A (es) 2006-03-21
IS7283A (is) 2004-05-21
KR100718371B1 (ko) 2007-05-14

Similar Documents

Publication Publication Date Title
ATE448238T1 (de) 3-beta-d-ribofuranosylthiazolo(4,5- delta)pyridimin-nucleoside und ihre verwendung
NO20024355L (no) Nukleosidforbindelser og anvendelser derav
HUS1500055I1 (hu) HIV-gátló pirimidinszármazékok
NO20025154L (no) Imidazopyrimidinderivater og triazolpyrimidinderivater
DK1303496T3 (da) Pyrimidinderivater
NO20034929L (no) 4-amino-5-fenyl-7-cyklobutylpyrrol(2,3-D)pyrimidinderivater
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
NO20006090D0 (no) Pyrrolo(2,3d)pyrimidin sammensetninger og anvendelse herav
NO20042742L (no) Pyrimidinforbindelser
NO20024308L (no) Arylsubstituerte pyridiner, pyrimidiner og triaziner og deres anvendelse
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
NO20032291D0 (no) Pyrimidinderivater
GB0112802D0 (en) Pyrimidine derivatives
GB0112803D0 (en) Pyrimidine derivatives
NO20042768L (no) IFNAR2 mutanter, deres fremstilling og anvendelse
ATE276260T1 (de) 2-aminoalkyl-thieno(2,3-d)pyrimidine
DE50202088D1 (de) Garmodulsystem
DK1325010T3 (da) Substituerede 3,4-dihydro-pyrimido[1,2-a]pyrimidiner og 3,4-dihydro-pyrazino[1,2-a]pyrimidiner
NO20031588D0 (no) Substituerte 3,4-dihydro-pyrimido(1,2-a)pyrimidiner og 3,4- dihydropyrazino(1,2-a)pyrimidiner
GB0119477D0 (en) Pyrimidine derivatives
GB0112804D0 (en) Pyrimidine derivatives
GB0119475D0 (en) Pyrimidine derivatives
GB0112807D0 (en) Pyrimidine derivatives
GB0112809D0 (en) Pyrimidine derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application